Format
Items per page

Send to:

Choose Destination

Links from PubMed

Items: 16

1.

oxaliplatin

A drug used with other drugs to treat colorectal cancer that is advanced or has come back. It is also being studied in the treatment of other types of cancer. Eloxatin attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound. [from NCI]

MedGen UID:
19128
Concept ID:
C0069717
Organic Chemical; Pharmacologic Substance
2.

DNA damage

Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. [from MeSH]

MedGen UID:
3880
Concept ID:
C0012860
Cell or Molecular Dysfunction
3.

Link brand of magnesium carbonate and aluminum hydroxide

brand of magnesium carbonate and aluminum hydroxide [from CHV]

MedGen UID:
60403
Concept ID:
C0208973
Inorganic Chemical; Pharmacologic Substance
4.

Uracil

A chemical compound that is used to make one of the building blocks of RNA. It is a type of pyrimidine. [from NCI]

MedGen UID:
22564
Concept ID:
C0041917
Biologically Active Substance; Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
5.

Fluorouracil

An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions. [from NCI]

MedGen UID:
5229
Concept ID:
C0016360
Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
6.

Clinical Response

An evaluation of the clinical response of the disease to the therapy. [from NCI]

MedGen UID:
887432
Concept ID:
C4055223
Finding
7.

Accumulation

An increase of substance (e.g., proteinaceous fluid and glycogen) in either the intracellular space, extracellular space, or within a hollow organ or structure. [from NCI_CDISC]

MedGen UID:
883922
Concept ID:
C4055506
Finding
8.

Visual Suppression

MedGen UID:
526147
Concept ID:
C0221103
Pathologic Function
9.

Fluoropyrimidine

Any fluoropyrimidine-based agent with potential antineoplastic activity. As an antimetabolite, a fluoropyrimidine interferes with pyrimidine utilization and incorporation into DNA and RNA. [from NCI]

MedGen UID:
452644
Concept ID:
C0596581
Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
10.

Fluorouracil response

5-fluorouracil is a chemotherapeutic agent, and a member of the fluoropyrimidine group of substances. It is mainly used to treat solid tumors, such as colorectal, breast and aerodigestive cancers. Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme for fluoropyrimidine metabolism and is therefore responsible for the detoxification of these types of drugs. Patients who are homozygous for variants in DPYD that lead to a non-functional protein, such as *2A or *13, have a high risk of severe or fatal drug toxicities and may benefit from receiving an alternative chemotherapeutic drug. Patients heterozygous for these variants also have an increased risk for drug toxicities, and reduced dosing is recommended for these individuals. Guidelines regarding the use of pharmacogenomic tests in dosing for 5-fluorouracil have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website (http://www.pharmgkb.org/drug/PA128406956). [from PharmGKB]

MedGen UID:
450455
Concept ID:
CN077983
Sign or Symptom
11.

5-[18F]Fluorouracil

The fluorine-18 (18F)-radiolabeled pyrimidine analog 5-fluorouracil (5-FU) with positron-emitting activity. Upon administration, 5-[18F]fluorouracil distribution in tumor tissue may be measured with positron emission tomography (PET). The degree of 5-[18F]fluorouracil uptake in tumor tissue may help to predict the response to 5-fluorouracil-based chemotherapy or to determine the response to other therapeutic agents used to treat 5-FU-sensitive tumors. [from NCI]

MedGen UID:
398465
Concept ID:
C2700356
Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance
12.

Mutant

An altered form of an individual, organism, population, or genetic character that differs from the corresponding wild type due to one or more alterations (mutations). [from NCI]

MedGen UID:
109303
Concept ID:
C0596988
Cell or Molecular Dysfunction
13.

cytotoxicity

The adverse effect of some iatrogenic therapies. It is an accepted side effect in radiation therapy where the desired effect is to kill rapidly growing tumor cells. In the killing of tumor cells, other cells that are rapidly growing e.g hair, mucous membranes are also killed. [from NCI]

MedGen UID:
108579
Concept ID:
C0596402
Cell or Molecular Dysfunction
14.

Down-regulation

A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. [from MeSH]

MedGen UID:
4386
Concept ID:
C0013081
Cell Function; Molecular Function
15.

Antineoplastic Agents

NOTE: Includes hormones (AN500) which are exclusively used as antineoplastics (e.g.,tamoxifen). Excludes other hormones (HS000). [from NDF-RT]

MedGen UID:
1984
Concept ID:
C0003392
Organic Chemical; Pharmacologic Substance
16.

Thymidylate Synthase Inhibitor DFP-11207

An orally available thymidylate synthase (TS) inhibitor with potential antineoplastic activity. Upon oral administration, DFP-11207 binds to and inhibits TS. This reduces thymine nucleotide synthesis, inhibits DNA synthesis and cell division, causes DNA damage and leads to tumor cell apoptosis. TS catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). [from NCI]

MedGen UID:
856470
Concept ID:
C3896876
Organic Chemical; Pharmacologic Substance
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center